| Literature DB >> 30048589 |
Younis Baqi1, Thanigaimalai Pillaiyar2, Aliaa Abdelrahman2, Olesja Kaufmann2, Samer Alshaibani2, Muhammad Rafehi2, Saman Ghasimi2, Rhalid Akkari2, Kirsten Ritter2, Katharina Simon3, Andreas Spinrath3, Evi Kostenis3, Qiang Zhao4, Meryem Köse2, Vigneshwaran Namasivayam2, Christa E Müller2.
Abstract
The orphan receptor GPR17 may be a novel drug target for inflammatory diseases. 3-(2-Carboxyethyl)-4,6-dichloro-1 H-indole-2-carboxylic acid (MDL29,951, 1) was previously identified as a moderately potent GPR17 agonist. In the present study, we investigated the structure-activity relationships (SARs) of 1. Substitution of the indole 1-, 5-, or 7-position was detrimental. Only small substituents were tolerated in the 4-position while the 6-position accommodated large lipophilic residues. Among the most potent compounds were 3-(2-carboxyethyl)-1 H-indole-2-carboxylic acid derivatives containing the following substituents: 6-phenoxy (26, PSB-1737, EC50 270 nM), 4-fluoro-6-bromo (33, PSB-18422, EC50 27.9 nM), 4-fluoro-6-iodo (35, PSB-18484, EC50 32.1 nM), and 4-chloro-6-hexyloxy (43, PSB-1767, EC50 67.0 nM). (3-(2-Carboxyethyl)-6-hexyloxy-1 H-indole-2-carboxylic acid (39, PSB-17183, EC50 115 nM) behaved as a partial agonist. Selected potent compounds tested at human P2Y receptor subtypes showed high selectivity for GPR17. Docking into a homology model of the human GPR17 and molecular dynamic simulation studies rationalized the observed SARs.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30048589 DOI: 10.1021/acs.jmedchem.7b01768
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446